Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Ordinary Shares, $0.0001 par value
-
Shares outstanding
-
33,549,784
-
Total 13F shares
-
20,823,195
-
Share change
-
+3,496,868
-
Total reported value
-
$212,304,432
-
Price per share
-
$10.20
-
Number of holders
-
32
-
Value change
-
+$35,784,994
-
Number of buys
-
18
-
Number of sells
-
6
Institutional Holders of Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA) as of Q2 2025
As of 30 Jun 2025,
Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,823,195 shares.
The largest 10 holders included
Karpus Management, Inc., First Trust Capital Management L.P., Polar Asset Management Partners Inc., GLAZER CAPITAL, LLC, Hudson Bay Capital Management LP, Westchester Capital Management, LLC, WOLVERINE ASSET MANAGEMENT LLC, MIZUHO SECURITIES USA LLC, ARISTEIA CAPITAL, L.L.C., and D. E. Shaw & Co., Inc..
This page lists
32
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.